索磷布韦维帕他韦治疗初治无肝硬化慢性丙肝:8周对比12周
RESOLVE为印度五家公立医院开展的多中心、开放标签、非劣效随机对照试验,将880例初治无肝硬化慢性HCV感染者按1:1分配接受索磷布韦400mg联合维帕他韦100mg治疗8周或12周。两组均无药物相关严重不良事件。
要点
- 8周索磷布韦维帕他韦方案在无肝硬化初治慢性丙肝中非劣效于12周标准方案。
- 两组均未发生药物相关严重不良事件或因不良事件停药。
核心结论
- 在无肝硬化的慢性HCV感染初治成人中,8周索磷布韦维帕他韦方案疗效与标准12周方案相似,支持缩短该类患者疗程。
研究设计与样本
- RESOLVE为在印度五家公立医院开展的多中心、开放标签、非劣效、随机对照试验,按1:1随机分配。
- 纳入初治、年龄≥18岁、无肝硬化的HCV单一感染成人,随机接受索磷布韦400mg联合维帕他韦100mg口服每日一次,疗程8周或12周。
- 共筛查1620例,纳入880例,12周组437例、8周组443例;女性455例(52%),男性425例(48%),中位年龄35岁(IQR 28至47)。
主要发现
- 816例(93%)完成既定8周或12周治疗及SVR12检测,其中12周组401/437例(92%)、8周组415/443例(94%)。
- 无参与者发生药物相关严重不良事件或因不良事件停药。
临床怎么用
- 对于无肝硬化的慢性HCV初治成人,可考虑采用8周索磷布韦维帕他韦方案以缩短疗程。
- 治疗决策仍需结合当地指南、药物可及性与患者个体情况。
局限性
- 研究为开放标签设计,未设盲。
- 研究在印度五家公立医院开展,外推至其他地区人群需谨慎。
- 纳入者为无肝硬化、初治、HCV单一感染者,不涵盖肝硬化或经治人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis C virus (HCV) infection without cirrhosis can be treated with 12 weeks of sofosbuvir-velpatasvir combination therapy. We aimed to assess whether a shorter 8-week treatment regimen of this combination was non-inferior to the standard 12-week regimen in successfully clearing HCV infection in HCV-infected patients without evidence of cirrhosis. METHODS: RESOLVE was a multicentre, open-label, non-inferiority, randomised controlled trial, conducted in five publicly funded hospitals in India. We randomly assigned (1:1) treatment-naive adults (aged ≥18 years) with non-cirrhotic HCV mono-infection to receive sofosbuvir 400 mg and velpatasvir 100 mg (orally, daily) for either 8 weeks or 12 weeks. The primary outcome was the proportion of participants with sustained virological response-ie, absence of quantifiable HCV RNA at 12 weeks after treatment completion (SVR12), with 95% assumed proportion with 12-week treatment, 5% non-inferiority margin, 2·5% one-sided alpha error, and 90% study power in the per-protocol population. The trial was registered with the Clinical Trial Registry of India, CTRI/2022/03/041368, and is complete. FINDINGS: Between May 15, 2022, and Sept 10, 2024, we screened 1620 participants, of whom 880 (54·3%) were enrolled in the study and randomly assigned to the 12-week (n=437 [50%]) or 8-week (n=443 [50%]) groups. 455 (52%) participants were women, 425 (48%) were men, and the median age was 35 years (IQR 28 to 47). 816 (93%) participants completed the intended 12-week (401 [92%] of 437) or 8-week (415 [94%] of 443) treatment and SVR12 testing. On per-protocol analysis, the proportion reaching SVR12 with 8-week treatment (410/415; 98·8% [95% CI 97·2 to 99·6]) was non-inferior to 12-week treatment (397/401; 99·0% [97·5 to 99·7]), with a risk difference of 0·2% (-1·5 to 1·9). Further, on intention-to-treat analysis, the proportion of participants reaching SVR12 with 8-week treatment (414/443; 93·5% [90·9 to 95·5]) was non-inferior to 12-week treatment (401/437; 91·8% [88·8 to 94·2]) with a risk difference of -1·7% (-5·2 to 1·9). No participant had any drug-related serious adverse event or drug discontinuation due to an adverse event. INTERPRETATION: An 8-week regimen of sofosbuvir-velpatasvir was similar in efficacy to the standard 12-week treatment in individuals with chronic HCV infection without cirrhosis. This finding supports shortening the duration of treatment in such patients. FUNDING: Indian Council of Medical Research, Department of Health Research, Government of India.
引用
- Goel A, Rungta S, Kumar V, et al. 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India. Lancet. 2026. PMID: 42815507. doi:10.1016/S0140-6736(26)01380-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。